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A Study to Explore the LDLR Gene Polymorphisms Contribute to Atorvastatin
Response in a Sample of Iraqi Population with Atherosclerotic Coronary Artery
Disease
Abstract
Genetic factors will determine the higher variability, which found in response to lipid reduction treatment
(statins). However, due to ethnicity the frequency and effect of single nucleotide polymorphisms (SNPs)
may differ. The main aim of lipid lowering medical treatment is to eventually prevent the endogenous
production of cholesterol through inhibition of HMG-CoA reductase, The resulting decrease in hepatocyte
cholesterol concentration triggers up-regulation of low-density lipoprotein (LDL)-receptor expression by
inducing sterol regulatory element-binding protein (SREBP) 2 cleavage, as SREBP-2 activates LDL receptor
transcription. The aim of this study was to evaluate the effects of low density lipoprotein receptor (LDL-R)
gene variants (rs200727689; rs72658860) in response to atorvastatin treatment in atherosclerotic
coronary artery disease (ACAD) in a sample of Iraqi patients. The genetic polymorphisms of rs200727689
and rs72658860 were studied in patients undergoing coronary angiography (CAG). One hundred Iraqi
patients include 52 patients treated with 20mg/day and 48 patients treated with 40mg/day, In addition,
100 apparently healthy subjects were genotype for these SNP by the thermal profile of allelic
discrimination methods used Real Time PCR (RT-PCR) assay. A significant increase in A allele frequency
(rs200727689) compared with controls for total ACAD patients (43% vs 23.5%; OR= 2.46; 95% C.I:
1.60-3.77; p=0.000). For (rs72658860) SNP, among total patients the A allele also increased the frequency
substantially compared with the controls (40.5% vs 23.5%; P=0.0003; OR= 2.22; 95% C.I: 1.44 -3.41). In the
patients who were treated with atorvastatin, SNP rs72658860 AA genotype significantly affected the
response of atorvastatin in dose 20mg compared with 40mg. The result showed in AA genotype of
(rs200727689) SNP a reduction in TC concentrations (277.55±108.38 vs 326.99±63.56) and LDL-C
concentrations (198.33±100.0 vs 250.01±62.52) in sera compared with GG genotype in patients treated
with 20 mg atorvastatin, although, none in all parameters statistically significant differences.
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1. Introduction

2. Materials and methods

The elevated plasma concentration of low-density
lipoprotein cholesterol (LDL-C) was highly correlated
as a major risk factor of coronary heart disease (CHD).
Clinical management of hypercholesterole with statins
not only improves the lipid profile, but also has
numerous atheroprotective impacts, decreasing cardiovascular mortality and morbidity [1]. Statins are
used for the treatment of cardiovascular disease and are
one of the most prescribed medication groups. Their
influence through HMGCR inhibition results decreased
intrahepatic cholesterol synthesis, hepatocyte surface
upregulation of low-density lipoprotein cholesterol
(LDL-C) receptors, increased hepatocyte LDL-C uptake, and decreased systemic LDL-C concentration [2].
Atorvastatin is used as a statin therapy abroad with
better safety and tolerance to lower the serum lipid
level, but some patients responded very poorly to the
statin therapy. Genome-wide association study
(GWAS) was observed the (single nucleotide polymorphisms) SNPs is related not just to the blood lipid
level, but also to the therapeutic effect of statin and a
spectrum of various responses among treated individuals were emerging [3]. This inter-individual
variation in therapeutic response can be determined by
several factors, including physiological and biological
conditions for patients, adherence to treatment, age,
gender, ethnicity and specific genetic factors for individuals [4].
In this context, the Pharmacogenetics (the branch
of pharmacology) discusses the role of genetic variation in the drug response of patients by correlating
gene expression or single nucleotide polymorphisms
(SNP) with the efficacy or toxicity of a drug. With
regard to the patient's genotype, it is opposed to the
growth of rational means to enhance drug therapy
with minimal side effects to maintain high efficacy
[5]. Atorvastatin is a class of statins used in Iraqi
healthcare services, screening for the response of
atorvastatin pharmacogenetics markers to the Iraqi
property population is of higher interest, but some of
the patients responded very poorly to the treatment of
statin [6].
In additon, the two polymorphisms (rs200727689;
rs72658860) assessed in this study as the low-density
lipoprotein receptor (LDL-R) is substantially associated with variability in the serum LDL-C level and
statin response.

2.1. Participants
This study was conducted in two hundred male and
female participants, their ages ranged between
(30e60) years, included ACAD patients (n ¼ 100) and
classified into two subgroups; patients treated with
20 mg atorvastatin (n ¼ 52), and patients treated with
40 mg (n ¼ 48) of atorvastatin therapy and they were
diagnosed according to the WHO criteria [7], based on
clinical examination, including chest pain plus either
electrocardiographic (ECG), echocardiography, treadmill test (TMT), and they have been asked to complete
clinical history of myocardial infarction (MI), angina
pectoris (stable and unstable). A structured questionnaire was used to identify cardiovascular risk factors
such as lipid profile, blood pressure, body mass index
(BMI) mass (Kg)/height (m)2, diabetes mellitus (FBS),
age and gender. Patients were selected from the Iraqi
center for heart disease at Ghazi Al-Hariri hospital/
Baghdad-Iraq for diagnosis and treatment. Neither of
the participants had diabetes hepatic, kidney endocrinological or malignant disease, nor they were receiving
lipid-lowering associated treatment. In addition,
apparently healthy participants of control (n ¼ 100)
were randomly selected for routine examinations.
2.2. Biochemical determinations
After a fast 12-h overnight, venipuncture was used
to get blood samples. Biochemical analysis was
calculated using conventional enzyme-colorimetric
(Biolabo/France) techniques and measured low-density
lipoprotein cholesterol using Friedewald formula on
which triglycerides did not exceed 400 mg/dL
(4.8 mmol/L). Pathological, normal and commercial
serums (Biolabo/France) have been used to verify the
validity of biochemical results.
2.3. Genetic and molecular analysis
Wizard Genomic DNA Purification Kit (Promega,
USA) was used to extract DNA from EDTA blood
samples. Genotyping was conducted by Taqman allelic
discrimination Real-time PCR assay. DNA isolation
was subjected for RT-PCR amplification of two SNPs
in LDL-R gene. The sequence of each primers and
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Table 1
Primers and Probes of LDL-R gene polymorphisms used in the study.
Sequence (5 ʹ3 ʹ)

Product size bp

F:5 ʹ -GCCAGCTTCCAGTGCAAC-3 ʹ
R:5 ʹ -TGGAACACGTAAAGACCCCT -3 ʹ
FAM-probe 5-GTGGGCCTGCGACAAC-3
VIC-probe 5 ʹ -CTGCAACAACGACCCCG-3
F:5 ʹ-CAGGGACCAACGAATGCTTG-3 ʹ
R:5 ʹ-AATCACCTTCGCATCTTCGC-3 ʹ
FAM-probe 5 ʹ -ACAACGGCGGCTGTTC-3 ʹ
VIC-probe 5 ʹ-AACGGCAGCTGTTCCC-3 ʹ

122

Primer/probes
LDL-R rs200727689

LDL-R rs72658860

129

probes used in the allelic discrimination, as shown in
(Table 1).
Real Time PCR was conducted in a complete
quantity of 25 ml containing 0.5 ml of forward and
reverse primers, 0.5 ml for each FAM and VIC sample,
12.5 ml TaqMan master mix, 6.5 ml PCR nuclease free
water, and 4 ml Genomic DNA. Real-time PCR is
original denaturation at 95C for 5 min accompanied by
5 denaturation cycles at 95C for 20 s, annealing at 60C
for 30 s.

compared by using the Chi-square test (c2) and Fisher's
exact test. Data were expressed as mean ± standard
deviation (SD) for continuous variables. Differences
between groups were analyzed by student's t-test preceded by Levene's test for equality of variances. The
Games-Howell and Scheffee Post Hoc tests for multiple comparison was applied after ANOVA tests. The
genotype frequencies of each SNP were measured for
each locus and tested for Hardy-Weinberg equilibrium
(HWE).

2.4. Data analysis

3. Results and discussion

Data analysis was conducted by using Statistical
Package for the Social Sciences (SPSS) for Windows,
version 22 (SPSS Inc. Chicago, Illinois, United States).
The Shapiro-Wilks test for normality was used to
determine if the studied parameters followed a
gaussian distribution. Categorical variables were
expressed as proportions. The proportions were

The clinical and demographic characteristics of the
patient subgroups, summarized in (Table 2). The results showed there were no statistically significant
differences in the two subgroups of ACAD in all parameters of demographic characteristics and lipid
profiles.

Table 2
Clinical and demographic characteristics of the study groups.
Parameters
a

Age (year)
Weight (kg)a
Height (cm)a
BMI (kg/m2)a
Systolic pressure (mmHg)a
Diastolic pressure (mmHg)a
TC (mg/dl)
TG (mg/dl)
HDL-C (mg/dl)
LDL-C (mg/dl)
VLDL (mg/dl)

Patients with 20 mg (n ¼ 52)

Patients with 40 mg (n ¼ 48)

P value

47.66 ± 9.25
79.04 ± 11.42
171.91 ± 9.00
27.96 ± 4.58
12.75 ± 4.12
7.05 ± 1.70
292.82 ± 81.42
160.36 ± 38.13
49.25 ± 5.00
212.52 ± 70.72
32.07 ± 7.62

48.08 ± 7.26
81.41 ± 12.47
170.37 ± 8.38
28.05 ± 3.70
11.21 ± 2.66
8.12 ± 3.29
322.90 ± 107.56
164.92 ± 59.78
48.68 ± 5.16
245.51 ± 103.58
32.98 ± 11.95

(NS)
(NS)
(NS)
(NS)
(NS)
(NS)
(NS)
(NS)
(NS)
(NS)
(NS)

Data were expressed as counts with percentages in parentheses or mean ± SD.
Statistical analysis performed by the Chi-squared test; NS, no significant differences.
a
Statistical analysis was performed by student t-test.
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Table (3A)
Numbers and percentage frequencies (Observed and Expected) of LDL-R gene (rs200727689 SNP) genotype and their Hardy-Weinberg equilibrium
(HWE) in patients and controls.
Genotype

GG
GA
AA
HWE Analysis

Patient (No. ¼ 100)

Control (No. ¼ 100)

Observed

Expected

Observed

Expected

No (%)

No (%)

No (%)

No (%)

35
44
21
c2

(35)
32.49 (32.49)
(44)
49.02 (49.02)
(21)
18.49 (18.49)
¼ 1.05, DF ¼ 1, P > 0.05

59
35
6
c2

(59)
58.52 (58.52)
(35)
35.96 (35.96)
(6)
5.52 (5.52)
¼ 0.07, DF ¼ 1, P > 0.05

1 degree of freedom (d.f) for Chi-squared distribution.

Table (3B)
Comparison of the Genotype and Allele Frequencies detected by Hardy-Weinberg equilibrium law of LDL-R gene polymorphism rs200727689
between Patient group and control group.
LDL-R gene at position þ502 (dbSNP-ID:rs200727689)

Groups

Genotypes
Patients (No. ¼ 100)
Controls (No. ¼ 100)

No.
%
No.
%

OR
EF or PF
P
95% (C.I.)

Alleles

GG

GA

AA

G

A

35
35%
59
59%
0.37
0.37
0.001
0.21e0.66

44
44%
35
35%
1.46
0.14
0.247
0.83e2.57

21
21%
6
6%
4.16
0.16
0.003
1.61e10.77

114
57%
153
76.5%
0.41
0.45
0.000
0.27e0.63

86
43%
47
23.5%
2.46
0.26
0.000
1.60e3.77

(OR): Odds Ratio (EF)Etiological Fraction (PF)Preventive Fraction; P: Fisher's Exact Probability.

Obesity, hypertension, diabetes mellitus, physical
inactivity, and smoking are all contributors to the
development of atherosclerotic coronary vascular disease [8].
3.1. Genotype and allele frequency distributions
This study examined the two LDL-R gene polymorphisms, the rs200727689 (G > A) SNP presented

in the (ligand-binding domain) at exon 4 and the
rs72658860 (G > A) SNP presented in the epidermal
growth factor precursor as domain (EGFP) at exon 7 to
determine the prospective impact of atherosclerosis
susceptibility by raising or reducing atherosclerosis.
The presence of genetic polymorphism was investigated by using Real-Time PCR (RT-PCR) thermal
profile of allelic discrimination techniques.

Table (4A)
Numbers and percentage frequencies (Observed and Expected) of LDL-R gene (rs72658860 SNP) genotype and their Hardy-Weinberg equilibrium
(HWE) in patients and controls.
Genotype

GG
GA
AA
HWE Analysis

Patient (No. ¼ 100)

Control (No. ¼ 100)

Observed

Expected

Observed

Expected

No (%)

No (%)

No (%)

No (%)

30
59
11
c2

(30)
35.4 (35.4)
(59)
48.2 (48.2)
(11)
16.4 (16.4)
¼ 5.03, DF ¼ 1, P < 0.05

1 degree of freedom (d.f) for Chi-squared distribution.

57
39
4
c2

(57)
58.52 (58.52)
(39)
35.96 (35.96)
(4)
5.52 (5.52)
¼ 1.05, DF ¼ 1, P > 0.05

S.Y. Abdulfattah et al. / Karbala International Journal of Modern Science 6 (2020) 44e52

47

Table (4B)
Comparison of the Genotype and Allele Frequencies detected by Hardy-Weinberg equilibrium law of LDL-R gene polymorphism rs72658860
between Patient group and control group.
LDL-R gene at position þ970 (dbSNP-ID: rs72658860)

Groups

Genotypes
Patients (No. ¼ 100)
Controls (No. ¼ 100)

No.
%
No.
%

(OR)
EF or PF
P
95% (C.I.)

Alleles

GG

GA

AA

G

A

30
30%
57
57%
0.32
0.39
0.0001
0.18e0.58

59
59%
39
39%
2.25
0.33
0.007
1.28e3.95

11
11%
4
4%
2.97
0.073
0.105
0.92e9.60

119
59.5%
153
76.5%
0.45
0.42
0.0003
0.29e0.69

81
40.5%
47
23.5%
2.22
0.22
0.0003
1.44e3.41

(OR): Odds Ratio (EF) Etiological Fraction (PF) Preventive Fraction; P: Fisher's Exact Probability.

Table (5A)
Impact of LDL-R polymorphism rs200727689 on the lipid profile of the control group.
Parameters

TC (mg/dl)
TG (mg/dl)
HDL (mg/dl)
LDL (mg/dl)
VLDL (mg/dl)
z
a
b
c

Genotype (mean þ SD)
G/G (n ¼ 59)

G/A (n ¼ 35)

A/A (n ¼ 6)

P valuez

136.82 ± 20.24
116.19 ± 20.27
52.81 ± 9.84
61.52 ± 19.01
23.11 ± 4.02

135.40 ± 18.36
106.17 ± 9.79a
50.93 ± 8.48
63.23 ± 18.85
21.44 ± 2.08

175.23 ± 27.94b,c
113.82 ± 22.26
49.79 ± 9.04
102.67 ± 20.94b,c
22.76 ± 4.45

0.000
0.03
0.54
0.000
0.09

ANOVA significance test (2-tailed).
P˂ 0.05 GG group vs. GA group.
P˂ 0.01 GG group vs. AA group.
P˂ 0.01 GA group vs. AA group.

3.1.1. LDL-R gene SNP at þ502 position
(rs200727689)
The LDL-R gene SNP at position þ502 (LDLRþ502)
was presented with three genotypes (GG, GA and AA)
that were corresponding to two alleles (G and A).
Hardy-Weinberg equilibrium (HWE) analysis showed
that there was no significant difference in patient or
control frequencies between the observed and expected
genotype frequencies (Table 3A).

Among these genotypes and alleles, it has been
found that the mutant allele homozygous (AA) has a
significant increase in the percentage of patients
compared with the control group (21% vs. 6%)
(P ¼ 0.003) and 4.16 (95% CI: 1.61e10.77;
EF ¼ 0.16) respectively. It was also observed that A
allele showed a significant increase frequency in patients (43% vs 23.5%; OR ¼ 2.46; 95% C.I:
1.60e3.77) (p ¼ 0.000). In the state of homozygosity

Table 5(B)
The lipid profile and atorvastatin therapy response to (20 mg/day) in the patients with atherosclerotic coronary artery disease, according to the lowdensity lipoprotein receptor (LDL-R) rs200727689 polymorphism.
Parameters

TC (mg/dl)
TG (mg/dl)
HDL (mg/dl)
LDL (mg/dl)
VLDL (mg/dl)
NS, no significance differences.
z
ANOVA test (2-tailed).

Genotype (mean þ SD)
G/G (n ¼ 21)

G/A (n ¼ 22)

A/A (n ¼ 9)

P valuez

300.0 ± 73.99
161.79 ± 56.88
47.00 ± 6.81
250.01 ± 62.52
32.35 ± 11.37

328.03 ± 123.01
176.35 ± 34.47
54.37 ± 6.23
274.12 ± 103.84
35.26 ± 6.88

266.90 ± 103.60
169.97 ± 42.72
45.22 ± 16.30
198.33 ± 100.0
34.00 ± 8.55

0.56
0.79
0.19
0.22
0.79

(NS)
(NS)
(NS)
(NS)
(NS)
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Table 5(C)
The lipid profile and atorvastatin therapy response to (40 mg/day) in the patients with atherosclerotic coronary artery disease, according to the lowdensity lipoprotein receptor (LDL-R) rs200727689 polymorphism.
Parameters

TC (mg/dl)
TG (mg/dl)
HDL (mg/dl)
LDL (mg/dl)
VLDL (mg/dl)
z
c

Genotype (mean þ SD)
P valuez

G/G (n ¼ 14)

G/A (n ¼ 22)

A/A (n ¼ 12)

293.61 ± 79.94
164.38 ± 37.36
46.66 ± 9.30
234.02 ± 26.16
32.87 ± 7.47

282.46 ± 74.91
148.20 ± 30.80
49.00 ± 9.13
203.86 ± 52.44
29.63 ± 6.17

394.24 ± 132.66
179.07 ± 86.07
45.50 ± 12.08
312.91 ± 122.26c
35.80 ± 17.21
c

0.047
0.47
0.71
0.01
0.47

ANOVA significance test (2-tailed).
P˂ 0.05 GA group vs. AA group.

Table 6(A)
Impact of LDL-R polymorphism rs72658860 on the lipid profile of the control group.
Parameters

TC (mg/dl)
TG (mg/dl)
HDL (mg/dl)
LDL (mg/dl)
VLDL (mg/dl)

Genotype (mean þ SD)
G/G (n ¼ 57)

G/A (n ¼ 39)

A/A (n ¼ 4)

P valuez

140.66 ± 24.03
113.40 ± 18.53
51.85 ± 9.77
66.13 ± 22.80
22.68 ± 3.70

134.69 ± 18.02
110.99 ± 18.17
52.17 ± 9.20
60.32 ± 18.49
22.19 ± 3.63

155.62 ± 20.27
107.93 ± 6.01
51.83 ± 9.47
82.20 ± 22.31
21.58 ± 1.20

0.13
0.73
0.98
0.11
0.73

(NS)
(NS)
(NS)
(NS)
(NS)

NS, no significance differences.
z
ANOVA test (2-tailed).

of the wild type allele (GG), there was a decrease
significant difference observed between patients and
control groups (35%vs 59%) (p ¼ 0.001) and the association OR was 0.37 (95% CI: 0.21e0.66;
PF ¼ 0.37), the G allele showed a significant difference
between patients and control groups respectively (57 v
76.5%; OR ¼ 0.41; 95C.I: 0.27e0.63) p ¼ 0.000. The
heterozygous (GA) has no significant difference between the two groups (44% vs 35%) OR ¼ 1.46 (95%
CI: 0.83e2.57; EF ¼ 0.14) P¼ (0.247) (Table 3B).

3.1.2. LDL-R gene SNP at þ970 position (rs72658860)
The LDL-R gene SNP at position þ970 (LDLRþ970)
was presented with three genotypes (GG, GA and AA)
that were corresponding to two alleles (G and A) in two
investigated groups. There was a significant difference
between the observed and expected genotype frequencies in patients, no significant difference between
the observed and expected genotype frequencies in
controls; therefore the Hardy-Weinberg equilibrium
HWE was established (Table 4A).

Table 6(B)
The lipid profile and atorvastatin therapy response to (20 mg/day) in the patients with atherosclerotic coronary artery disease, according to the lowdensity lipoprotein receptor (LDL-R) rs72658860 polymorphism.
Parameters

TC (mg/dl)
TG (mg/dl)
HDL (mg/dl)
LDL (mg/dl)
VLDL (mg/dl)
z
a
c

Genotype (mean þ SD)
P valuez

G/G (n ¼ 7)

G/A (n ¼ 18)

A/A (n ¼ 4)

277.30 ± 88.70
151.80 ± 30.71
52.71 ± 7.06
183.54 ± 47.60
30.36 ± 6.14

361.46 ± 98.62
152.16 ± 34.64
48.55 ± 10.81
279.50 ± 60.00a
30.43 ± 6.92

256.45 ± 64.05
148.66 ± 39.08
52.25 ± 8.73
179.97 ± 43.30c
29.73 ± 7.81

ANOVA significance test (2-tailed).
P˂ 0.05 GG group vs. GA group.
P˂ 0.05 GA group vs. AA group.

c

0.049
0.97
0.57
0.000
0.97
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Table 6(C)
The lipid profile and atorvastatin therapy response to (40 mg/day) in the patients with atherosclerotic coronary artery disease, according to the lowdensity lipoprotein receptor (LDL-R) rs72658860 polymorphism.
Parameters

TC (mg/dl)
TG (mg/dl)
HDL (mg/dl)
LDL (mg/dl)
VLDL (mg/dl)

Genotype (mean þ SD)
G/G (n ¼ 9)

G/A (n ¼ 19)

A/A (n ¼ 3)

P valuez

313.33 ± 119.65
161.20 ± 30.97
48.60 ± 5.15
234.02 ± 49.62
32.24 ± 6.18

328.87 ± 68.86
158.12 ± 37.11
47.92 ± 4.68
250.36 ± 66.89
31.62 ± 7.42

356.40 ± 56.22
151.60 ± 48.40
53.40 ± 5.68
274.00 ± 66.63
30.32 ± 9.68

0.62
0.87
0.08
0.43
0.87

(NS)
(NS)
(NS)
(NS)
(NS)

NS, no significance differences.
z
ANOVA test (2-tailed).

There was no significant difference in the distribution of homozygous wild type (GG) between patients
and controls (30% vs 57%; OR ¼ 0.32; 95% C.I:
0.18e0.58; PF ¼ 0.39). In addition, there were no
significant differences observed in the mutant allele
(AA) in comparison with two groups (11% vs 4%;
p ¼ 0.007; OR ¼ 2.97; 95% C.I: 0.92e9.60;
EF ¼ 0.073). Comparing patients to control revealed
that G and A allele frequency were significant differences, the G allele decreases in patients by comparing
with control (59.5% vs 76.5%; P ¼ 0.0003; OR ¼ 0.45;
95% C.I: 0.29e0.69) and the A allele increase in patients compared with control group (40.5% vs 23.5%;
P ¼ 0.0003; OR ¼ 2.22; 95% C.I: 1.44e3.41). The
heterozygous genotype has a significant difference
observed between the two groups (59% vs 39%;
P ¼ 0.007; OR ¼ 2.25; C.I: 1.28e3.95; EF ¼ 0.33)
(Table 4B).
It is possible to consider A as a predisposing allele
for ACAD, while G allele may have a protective effect
against the development of disease. These findings
came in line with the presented results from Ref. [9] in
Portuguese atherosclerotic coronary artery disease patients, in which significant variation between patients
and controls was observed in genotype distribution of
rs200727689. An earlier study related to these results
[10], demonstrated pathogenicity of the rs72658860
SNP and highly distributed in patients with hypercholesterol in Mexican individuals, and [11] showed
the predisposing effect of cardiovascular disease
occurred with relatively high frequencies in specific
parts of the Netherlands.
3.2. The pharmacogenetic effect of single nucleotide
polymorphisms (SNPs) on lipid-lowering response to
atrovastatins
Atorvastatin controls elevated levels of cholesterol
and reduces the risk of heart disease; therefore,
studying the association between susceptible gene

polymorphism and lipid-reducing efficacy is a great
benefit to the clinical application of atorvastatin [12].
Recently, a major focus has been on the genetic factor
as a major contributor to a drug response, but a continuum of different responses across treated persons
has appeared when an equivalent dosage is used [13].
Atorvastatin is one of those whose drug effectiveness is
affected by both genetic and environmental factors.
Thus, studying the association between lipid-lowering
effectiveness and susceptible gene polymorphism is
very important for clinical application of atorvastatin
[12].
3.2.1. Pharmacogenetics effect of rs200727689
The levels of serum lipid in control and patients
that treated with (20 mg and 40 mg) according to
rs200727689 genotype are shown in Table (5A) (5B)
and (5C) respectively. In the control group, the
plasma level of total cholesterol was significantly
higher in the AA genotype than in the GG and GA
genotype (175.23 ± 27.94 vs 136.82 ± 20.24) and
(175.23 ± 27.94 vs 135.40 ± 18.36) P¼ (0.000), also
the plasma LDL-C was significantly higher in AA
genotype than in the GG and GA genotype
(102.67 ± 20.94 vs 61.52 ± 19.01) and
(102.67 ± 20.94 vs 63.23 ± 18.85) P¼ (0.000). The
plasma level of triglyceride was significantly
decreased in GA genotype compared with GG genotype (106.17 ± 9.79 vs 116.19 ± 20.27) P¼ (0.03).
Other parameters such as HDL and VLDL were not
significantly different between various genotypes in
the control group.
The results showed no statistically significant differences in patients treated with atorvastatin 20 mg in
all parameters (TC, TG, HDL, LDL, and VLDL)
p > 0.05, but the result in AA genotype observed
reduction in TC (277.55 ± 108.38 vs 326.99 ± 63.56)
and LDL-C (198.33 ± 100.0 vs 250.01 ± 62.52) concentration in sera of patients treated with 20 mg atorvastatin compare with GG genotype.
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Interestingly, the minor allele (A) of rs200727689
has been linked to an improved response to 20 mg
atorvastatin treatment.
In addition, A allele homozygous carriers had the
highest serum level of total and LDL cholesterol in
patients treated with 40 mg atorvastatin compared with
GA genotype (394.24 ± 132.66 vs 282.46 ± 74.91)
P ¼ 0.047 and (312.91 ± 122.26 vs 203.86 ± 52.44)
P¼ (0.01) respectively. There were no significant differences in other parameters in patients with 40 mg
atorvastatin between various genotypes.
3.2.2. Pharmacogenetics effect of rs72658860
The serum lipid levels in control and patients
treated with (20 mg and 40 mg) subgroup participants
according to rs72658860 genotype are shown in table
(6A) (6B) and (6C) respectively. In the control group,
there were no significant differences observed in all
parameters of the lipid profile P > 0.05 between
various genotypes, the result was a small increase in
AA genotype TC and LDL-C serum levels compared
with GG and GA.
The results in patients treated with 20 mg atorvastatin observed decrease in TC in GG and AA genotypes but significantly occurred in AA compared with
GA genotype (256.45 ± 64.05 vs 361.46 ± 98.62)
P ¼ 0.049, also a significant reduction in LDL-C serum
level between GG and GA genotypes (183.54 ± 47.60
vs 279.50 ± 60.00), and between AA and GA genotypes (179.97 ± 43.30 vs 279.50 ± 60.00), there were
no significant differences observed in other parameters
between various genotypes.
The serum lipid level in patients treated with 40 mg
atorvastatin was observed there were no significant
differences in all biochemical parameters with regard
to rs72658860 SNP.
The association between homozygous carriers of A
allele and response to atorvastatin medication has been
revealed, according to this study. Despite the dose of
40 mg/day atorvastatin treatment, it should confirm
that treatment with 40 mg/day of atorvastatin had been
inadequate to reduce the levels of lipid to recommended target values and improvement seen in 20 mg/
day of atorvastatin in both TC and LDL-C.
In relation to pharmacogenetics of atorvastatin
therapy, one of the variants showing more reproducibility with treatment response is the AA genotype in
20 mg patients compared to 40 mg in rs200727689,
this allele changed from highly hydrophilic polar
amino acid (aspartic acid) to polar amino acid (asparagine) of exon 4 [14]. It was found that the AA genotype of rs72658860 was significantly associated with

the response to 20 mg atorvastatin; this allele changed
the polar amino acid glycine to serine [9].
Atorvastatin is a relatively lipophilic compound and
is the most effective in reducing low-density lipoprotein
cholesterol, providing a rational basis for its use in lowdose clinical practice [15]. The lipophilic statin appears
to have a higher level of non-hepatic cell exposure and
passive non-selective access to both hepatic and nonhepatic tissues [16,17]. The hypolipedimic activity of
statins is modified by genetic factors. There have been
found several gene polymorphisms that affect statin
activity, however pharmacogenetic variability may also
be a risk factor for adverse drug response [18].
Studies show that atorvastatin reduces total blood
cholesterol and LDL-cholesterol in a linear dose-related
manner over the commonly prescribed dose range; the
effect was higher at lower doses than at higher doses
[19]. The results suggested by Ref. [20] that the hypolipidemic activity manifested at the dose-dependent of
atorvastatin (20 mg/day), which characterized by a
decrease in both cholesterol levels and the atherogenic
index. Treatment with low-dose atorvastatin appears to
be safe and well tolerated in early-stage patients,
reducing total cholesterol, LDL-C, oxLDL, and therefore helping to improve vascular functions [21].
Likewise, the result was confirmed by Ref. [22] who
observed a significant reduction in atorvastatin 20 mg/
day in four surrogate markers following administration
of atorvastatin in both patients and control groups, and
[23] suggested that the aggressive treatment with statins is not more effective for controlling lipid levels
and cannot prevent future ischemic events. Such differences with [24] who suggests the intensive lipidlowering therapy with 80 mg of atorvastatin per day in
patients with stable (CHD) provides significant clinical
benefits beyond that afforded by treatment with 10 mg
of atorvastatin per day. It has been reported that the
response to statins has been affected by the mutation
class in reducing LDL and apolipoprotein B. After
treatment with statins, the patient with class V mutations in which the internalized LDL particles cannot be
released into the endosomes shows a high reduction in
LDL and apolipoprotein B levels [25]. Furthermore,
the answer differs among individuals, possibly due to
factors such as gender, ethnicity or genetic composition patients of Asian ancestry have greater lipid
reduction activity compared with European ancestry at
lower doses of atorvastatin and rosuvastatin [26,27].
In previous studies, two SNPs in the LDL-R gene
(rs1433099) and (rs5925) have been identified to be
associated with lipid-lowering. The first polymorphism
has a significant association between lower levels of
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LDL-C and cardiovascular disease with pravastatintreated patients with coronary heart disease [28]. The
latter SNP seems capable to significantly influence of
the LDL-C response to pravastatin in patients with
hypercholesterolemia [29]. From the previously available data [2], concluded that carriers of the E4 (ℇ 4)
allele of the ApoE gene tend to have a greater percentage reduction in LDL cholesterol in response to
statin therapy than participants carrying the wild-type
ApoE allele (E3 or ℇ 3).
4. Conclusion
Finally, it may be concluded that, this study is the
first to identify the LDL-R-gene variants related to the
dose-response of atorvastatin to lower the TC and
LDL-C serum level with a specific genotypes. The
study showed that the two SNPs of LDL-R gene
(rs200727689; rs72658860) affected the atorvastatin
effectiveness in all the treated patients and revealed an
effective response to 20 mg of atorvastatin in the Iraqi
population in reduction of TC and LDL-C with AA
genotype and it was observed in rs72658860. Whereas
the toxicity and efficacy are related to the statin dose,
carriers of these SNPs may be benefit more from the
high potency of 20 mg atorvastatin to achieve
aggressive aims; these findings can provide a basis for
customized therapy for cardiovascular disease patients.
In order to confirm our findings, future studies with
large sample sizes are required.
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